American Gene Technologies

[Available On-Demand]
American Gene Technologies (AGT) is a clinical-stage gene and cell therapy company with a proprietary gene-delivery platform for rapid development of cell and gene therapies to cure infectious diseases, cancers, and inherited disorders. The Company’s mission is to transform people’s lives through genetic medicines that rid the body of disease. The company's lead program in the clinic is an autologous cell therapy designed as a single treatment cure for HIV. AGT has received eight patents for its unique immuno-oncology approach to stimulate gamma-delta (γδ) T cells to destroy a variety of solid tumors. The Company has developed a synthetic gene for treating Phenylketonuria (PKU), a debilitating inherited disease. AGT’s treatment for PKU has been granted Orphan Drug Designation by the Food and Drug Administration (FDA) and it is expected to reach the clinic in 2021
Company Type:
Privately Funded Company
Company HQ State:
Maryland
Company HQ Country:
United States
Year Founded:
2008
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
AGT103-T - autologous cell therapy designed as a functional cure for HIV
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
photo
Chief Executive Officer
American Gene Technologies International Inc.